-
1
-
-
79958043675
-
-
Vintage 2009 populations), National Cancer Institute. Bethesda MD based on November 2011 SEER data submission, posted to the SEER web site
-
Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) SEER cancer statistics review, 1975-2009 (Vintage 2009 populations), National Cancer Institute. Bethesda, MD, http://seer. cancer.gov/csr/1975-2009-pops09/, based on November 2011 SEER data submission, posted to the SEER web site, 2012
-
(2012)
SEER Cancer Statistics Review 1975-2009
-
-
Howlader, N.1
Noone, A.M.2
Krapcho, M.3
Neyman, N.4
Aminou, R.5
Altekruse, S.F.6
Kosary, C.L.7
Ruhl, J.8
Tatalovich, Z.9
Cho, H.10
Mariotto, A.11
Eisner, M.P.12
Lewis, D.R.13
Chen, H.S.14
Feuer, E.J.15
Cronin, K.A.16
-
2
-
-
84869210903
-
How much of a good thing? What duration for interferon alfa-2b adjuvant therapy?
-
Tarhini AA, Kirkwood JM (2012) How much of a good thing? What duration for interferon Alfa-2b adjuvant therapy? J Clin Oncol 30(31):3773-3776
-
(2012)
J Clin Oncol
, vol.30
, Issue.31
, pp. 3773-3776
-
-
Tarhini, A.A.1
Kirkwood, J.M.2
-
3
-
-
74949143594
-
Final version of 2009 AJCC melanoma staging and classification
-
Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199-6206
-
(2009)
J Clin Oncol
, vol.27
, Issue.36
, pp. 6199-6206
-
-
Balch, C.M.1
Gershenwald, J.E.2
Soong, S.J.3
-
4
-
-
58149375115
-
Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: A multicenter study in 388 patients with positive sentinel nodes
-
van Akkooi AC, Nowecki ZI, Voit C et al (2008) Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: A multicenter study in 388 patients with positive sentinel nodes. Ann Surg 248(6): 949-955
-
(2008)
Ann Surg
, vol.248
, Issue.6
, pp. 949-955
-
-
Van Akkooi, A.C.1
Nowecki, Z.I.2
Voit, C.3
-
5
-
-
53549087527
-
How tumors escape mass destruction
-
Stewart TJ, Abrams SI (2008) How tumors escape mass destruction. Oncogene 27:5894-5903
-
(2008)
Oncogene
, vol.27
, pp. 5894-5903
-
-
Stewart, T.J.1
Abrams, S.I.2
-
6
-
-
0029774810
-
Interleukin 10 production by human melanoma
-
Sato T, McCue P, Masuoka K et al (1996) Interleukin 10 production by human melanoma. Clin Cancer Res 2:1383-1390
-
(1996)
Clin Cancer Res
, vol.2
, pp. 1383-1390
-
-
Sato, T.1
McCue, P.2
Masuoka, K.3
-
7
-
-
0030724702
-
Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma
-
Enk AH, Jonuleit H, Saloga J, Knop J (1997) Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 73:309-316
-
(1997)
Int J Cancer
, vol.73
, pp. 309-316
-
-
Enk, A.H.1
Jonuleit, H.2
Saloga, J.3
Knop, J.4
-
8
-
-
0033047725
-
Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions
-
Kirkwood JM, Farkas DL, Chakraborty A et al (1999) Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions. Mol Med 5(1):11-20
-
(1999)
Mol Med
, vol.5
, Issue.1
, pp. 11-20
-
-
Kirkwood, J.M.1
Farkas, D.L.2
Chakraborty, A.3
-
9
-
-
33745989541
-
Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses
-
Moschos SJ, Edington HD, Land SR et al (2006) Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 24(19):3164-3171
-
(2006)
J Clin Oncol
, vol.24
, Issue.19
, pp. 3164-3171
-
-
Moschos, S.J.1
Edington, H.D.2
Land, S.R.3
-
10
-
-
79953087601
-
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment
-
Gajewski TF, Fuertes M, Spaapen R et al (2011) Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol 23(2):286-292
-
(2011)
Curr Opin Immunol
, vol.23
, Issue.2
, pp. 286-292
-
-
Gajewski, T.F.1
Fuertes, M.2
Spaapen, R.3
-
11
-
-
34249709048
-
Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma
-
Critchley-Thorne RJ, Yan N, Nacu S et al (2007) Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 4(5): E176
-
(2007)
PLoS Med
, vol.4
, Issue.5
-
-
Critchley-Thorne, R.J.1
Yan, N.2
Nacu, S.3
-
12
-
-
79955561959
-
Interferon signaling patterns in peripheral blood lymphocytes
-
may predict clinical outcome after high-dose interferon therapy in melanoma patients
-
Simons DL, Lee G, Kirkwood JM, Lee PP (2011) Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients. J Transl Med 9:52
-
(2011)
J Transl Med
, vol.9
, pp. 52
-
-
Simons, D.L.1
Lee, G.2
Kirkwood, J.M.3
Lee, P.P.4
-
13
-
-
0030030347
-
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The eastern cooperative oncology group trial est 1684
-
Kirkwood JM, Strawderman MH, Ernstoff MS et al (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7-17
-
(1996)
J Clin Oncol
, vol.14
, pp. 7-17
-
-
Kirkwood, J.M.1
Strawderman, M.H.2
Ernstoff, M.S.3
-
14
-
-
1842533233
-
A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma
-
Kirkwood JM, Manola J, Ibrahim J et al (2004) A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 10(5):1670-1677
-
(2004)
Clin Cancer Res
, vol.10
, Issue.5
, pp. 1670-1677
-
-
Kirkwood, J.M.1
Manola, J.2
Ibrahim, J.3
-
15
-
-
0034088027
-
High-and low-dose interferon alfa-2b in high-risk melanoma: Fi rst analysis of intergroup trial E1690/S9111/C9190
-
Kirkwood JM, Ibrahim JG, Sondak VK et al (2000) High-and low-dose interferon alfa-2b in high-risk melanoma: Fi rst analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18(12):2444-2458
-
(2000)
J Clin Oncol
, vol.18
, Issue.12
, pp. 2444-2458
-
-
Kirkwood, J.M.1
Ibrahim, J.G.2
Sondak, V.K.3
-
16
-
-
0035339880
-
High-dose interferon alfa-2b signifi -cantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/ S9512/C509801
-
Kirkwood JM, Ibrahim JG, Sosman JA et al (2001) High-dose interferon alfa-2b signifi -cantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/ S9512/C509801. J Clin Oncol 19(9): 2370-2380
-
(2001)
J Clin Oncol
, vol.19
, Issue.9
, pp. 2370-2380
-
-
Kirkwood, J.M.1
Ibrahim, J.G.2
Sosman, J.A.3
-
17
-
-
0028872887
-
Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma
-
Creagan ET, Dalton RJ, Ahmann DL et al (1995) Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 13(11):2776-2783
-
(1995)
J Clin Oncol
, vol.13
, Issue.11
, pp. 2776-2783
-
-
Creagan, E.T.1
Dalton, R.J.2
Ahmann, D.L.3
-
18
-
-
0035281923
-
High-dose interferon alfa-2b does not diminish antibody response to gm2 vaccination in patients with resected melanoma: Results of the multicenter eastern cooperative oncology group phase ii trial e2696
-
Kirkwood JM, Ibrahim J, Lawson DH et al (2001) High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol 19(5):1430-1436
-
(2001)
J Clin Oncol
, vol.19
, Issue.5
, pp. 1430-1436
-
-
Kirkwood, J.M.1
Ibrahim, J.2
Lawson, D.H.3
-
19
-
-
84859460536
-
Intensifi ed high-dose intravenous interferon alpha 2b (ifna2b) for adjuvant treatment of stage iii melanoma: A randomized phase iii italian melanoma intergroup IMI) trial [isrctn75125874
-
for Italian Melanoma Intergroup (IMI suppl):abstr 8506
-
Chiarion-Sileni V, Guida M, Romanini A et al for Italian Melanoma Intergroup (IMI) (2011) Intensifi ed high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III melanoma: A randomized phase III Italian Melanoma Intergroup (IMI) trial [ISRCTN75125874]. J Clin Oncol 29(suppl):abstr 8506
-
(2011)
J Clin Oncol
, vol.29
-
-
Chiarion-Sileni, V.1
Guida, M.2
Romanini, A.3
-
20
-
-
25844465690
-
Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): Randomised controlled trial
-
Eggermont AM, Suciu S, MacKie R et al (2005) Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): Randomised controlled trial. Lancet 366(9492):1189-1196
-
(2005)
Lancet
, vol.366
, Issue.9492
, pp. 1189-1196
-
-
Eggermont, A.M.1
Suciu, S.2
MacKie, R.3
-
21
-
-
77952469658
-
Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: Prognostic significance of autoantibodies -EORTC 18991
-
Bouwhuis MG, Suciu S, Testori A et al (2010) Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: Prognostic significance of autoantibodies -EORTC 18991. J Clin Oncol 28(14): 2460-2466
-
(2010)
J Clin Oncol
, vol.28
, Issue.14
, pp. 2460-2466
-
-
Bouwhuis, M.G.1
Suciu, S.2
Testori, A.3
-
22
-
-
79151485188
-
Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (nordic ifn trial): A randomised phase 3 trial
-
Hansson J, Aamdal S, Bastholt L et al (2011) Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): A randomised phase 3 trial. Lancet Oncol 12(2):144-152
-
(2011)
Lancet Oncol
, vol.12
, Issue.2
, pp. 144-152
-
-
Hansson, J.1
Aamdal, S.2
Bastholt, L.3
-
23
-
-
7144264391
-
Adjuvant interferon alfa-2a treatment in resected primary stage ii cutaneous melanoma austrian malignant melanoma cooperative group
-
Pehamberger H, Soyer HP, Steiner A et al (1998) Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 16(4):1425-1429
-
(1998)
J Clin Oncol
, vol.16
, Issue.4
, pp. 1425-1429
-
-
Pehamberger, H.1
Soyer, H.P.2
Steiner, A.3
-
24
-
-
7144228601
-
Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases french cooperative group on melanoma
-
Grob JJ, Dreno B, de la Salmonière P et al (1998) Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 351(9120): 1905-1910
-
(1998)
Lancet
, vol.351
, Issue.9120
, pp. 1905-1910
-
-
Grob, J.J.1
Dreno, B.2
De La Salmonière, P.3
-
25
-
-
0035883950
-
Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: A randomised trial
-
Cascinelli N, Belli F, MacKie RM et al (2001) Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: A randomised trial. Lancet 358(9285):866-869
-
(2001)
Lancet
, vol.358
, Issue.9285
, pp. 866-869
-
-
Cascinelli, N.1
Belli, F.2
MacKie, R.M.3
-
26
-
-
0035805053
-
Adjuvant interferon alpha 2b in high risk melanoma - The Scottish study
-
Cameron DA, Cornbleet MC, Mackie RM et al (2001) Adjuvant interferon alpha 2b in high risk melanoma -the Scottish study. Br J Cancer 84(9):1146-1149
-
(2001)
Br J Cancer
, vol.84
, Issue.9
, pp. 1146-1149
-
-
Cameron, D.A.1
Cornbleet, M.C.2
Mackie, R.M.3
-
27
-
-
1642554821
-
Final results of the eortc 18871/dkg 80-1 randomised phase iii trial rifn-alpha2b versus rifn-gamma versus iscador m versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis
-
for EORTC Melanoma Group in cooperation with the German Cancer Society (DKG) et al
-
Kleeberg UR, Suciu S, Bröcker EB, for EORTC Melanoma Group in cooperation with the German Cancer Society (DKG) et al (2004) Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 40(3):390-402
-
(2004)
Eur J Cancer
, vol.40
, Issue.3
, pp. 390-402
-
-
Kleeberg, U.R.1
Suciu, S.2
Bröcker, E.B.3
-
28
-
-
3242686449
-
Adjuvant interferon in high-risk melanoma: The aim high study -united kingdom coordinating committee on cancer research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in highrisk resected malignant melanoma
-
Hancock BW, Wheatley K, Harris S et al (2004) Adjuvant interferon in high-risk melanoma: The AIM HIGH Study -United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in highrisk resected malignant melanoma. J Clin Oncol 22(1):53-61
-
(2004)
J Clin Oncol
, vol.22
, Issue.1
, pp. 53-61
-
-
Hancock, B.W.1
Wheatley, K.2
Harris, S.3
-
29
-
-
77649217618
-
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: Results of a randomized phase III DeCOG trial
-
Hauschild A, Weichenthal M, Rass K et al (2010) Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: Results of a randomized phase III DeCOG trial. J Clin Oncol 28(5): 841-846
-
(2010)
J Clin Oncol
, vol.28
, Issue.5
, pp. 841-846
-
-
Hauschild, A.1
Weichenthal, M.2
Rass, K.3
-
30
-
-
44849131339
-
Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: A prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis
-
Garbe C, Radny P, Linse R et al (2008) Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: A prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol 19(6):1195-1201
-
(2008)
Ann Oncol
, vol.19
, Issue.6
, pp. 1195-1201
-
-
Garbe, C.1
Radny, P.2
Linse, R.3
-
31
-
-
84859386046
-
Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate-and high-risk melanoma (Intergroup trial E1697
-
suppl): Abstr 8505
-
Agarwala SS, Lee SJ, Flaherty LE et al (2011) Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate-and high-risk melanoma (Intergroup trial E1697). J Clin Oncol 29(suppl): Abstr 8505
-
(2011)
J Clin Oncol
, vol.29
-
-
Agarwala, S.S.1
Lee, S.J.2
Flaherty, L.E.3
-
32
-
-
60849108348
-
Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma
-
Pectasides D, Dafni U, Bafaloukos D et al (2009) Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol 27(6): 939-944
-
(2009)
J Clin Oncol
, vol.27
, Issue.6
, pp. 939-944
-
-
Pectasides, D.1
Dafni, U.2
Bafaloukos, D.3
-
33
-
-
46749103710
-
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: Fi nal results of EORTC 18991, a randomised phase III trial
-
Eggermont AM, Suciu S, Santinami M et al (2008) Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: Fi nal results of EORTC 18991, a randomised phase III trial. Lancet 372(9633):117-126
-
(2008)
Lancet
, vol.372
, Issue.9633
, pp. 117-126
-
-
Eggermont, A.M.1
Suciu, S.2
Santinami, M.3
-
34
-
-
84869212118
-
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma
-
Eggermont AM, Suciu S, Testori A et al (2012) Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol 30(31):3810-3818
-
(2012)
J Clin Oncol
, vol.30
, Issue.31
, pp. 3810-3818
-
-
Eggermont, A.M.1
Suciu, S.2
Testori, A.3
-
35
-
-
0041409703
-
Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefi t? A meta-analysis of the randomised trials
-
Wheatley K, Ives N, Hancock B et al (2003) Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefi t? A meta-analysis of the randomised trials. Cancer Treat Rev 29:241-252
-
(2003)
Cancer Treat Rev
, vol.29
, pp. 241-252
-
-
Wheatley, K.1
Ives, N.2
Hancock, B.3
-
36
-
-
77950576363
-
Interferon alpha adjuvant therapy in patients with high-risk melanoma: A systematic review and metaanalysis
-
Mocellin S, Pasquali S, Rossi CR et al (2010) Interferon alpha adjuvant therapy in patients with high-risk melanoma: A systematic review and metaanalysis. J Natl Cancer Inst 102:493-501
-
(2010)
J Natl Cancer Inst
, vol.102
, pp. 493-501
-
-
Mocellin, S.1
Pasquali, S.2
Rossi, C.R.3
-
37
-
-
0036534376
-
Interferon alfa therapy for malignant melanoma: A systematic review of randomized controlled trials
-
Lens MB, Dawes M (2002) Interferon alfa therapy for malignant melanoma: A systematic review of randomized controlled trials. J Clin Oncol 20:1818-1825
-
(2002)
J Clin Oncol
, vol.20
, pp. 1818-1825
-
-
Lens, M.B.1
Dawes, M.2
-
38
-
-
35649015750
-
Interferon-{alpha} as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials
-
abstract 8526
-
Wheatley K, Hancock B, Gore M et al (2007) Interferon-{alpha} as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials. J Clin Oncol 25(18 suppl):abstract 8526
-
(2007)
J Clin Oncol
, vol.25
, Issue.18 SUPPL.
-
-
Wheatley, K.1
Hancock, B.2
Gore, M.3
-
39
-
-
84891798224
-
Active immunization toward the mage-a3 antigen in patients with metastatic melanoma: Fouryear follow-up results from a randomized phase ii study (eortc16032-18031
-
suppl): Abstr 8535
-
Kruit W, Suciu S, Dreno B et al (2011) Active immunization toward the MAGE-A3 antigen in patients with metastatic melanoma: Fouryear follow-up results from a randomized phase II study (EORTC16032-18031). J Clin Oncol 29(suppl): Abstr 8535
-
(2011)
J Clin Oncol
, vol.29
-
-
Kruit, W.1
Suciu, S.2
Dreno, B.3
-
40
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi FS, O'Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711-723
-
(2010)
N Engl J Med
, vol.363
, Issue.8
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
-
41
-
-
79959772576
-
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
-
Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517-2526
-
(2011)
N Engl J Med
, vol.364
, Issue.26
, pp. 2517-2526
-
-
Robert, C.1
Thomas, L.2
Bondarenko, I.3
-
42
-
-
84864285704
-
Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial
-
Hauschild A, Grob JJ, Demidov LV et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839):358-342
-
(2012)
Lancet
, vol.380
, Issue.9839
, pp. 358-342
-
-
Hauschild, A.1
Grob, J.J.2
Demidov, L.V.3
-
43
-
-
84863673204
-
Improved survival with MEK inhibition in BRAF-mutated melanoma
-
Flaherty KT, Robert C, Hersey P et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367(2):107-114
-
(2012)
N Engl J Med
, vol.367
, Issue.2
, pp. 107-114
-
-
Flaherty, K.T.1
Robert, C.2
Hersey, P.3
-
44
-
-
77954373338
-
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function
-
Boni A, Cogdill AP, Dang P et al (2010) Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 70(13):5213-5219
-
(2010)
Cancer Res
, vol.70
, Issue.13
, pp. 5213-5219
-
-
Boni, A.1
Cogdill, A.P.2
Dang, P.3
-
45
-
-
84863393623
-
Selective BRAF inhibitors induce marked T-cell infi ltration into human metastatic melanoma
-
Wilmott JS, Long GV, Howle JR et al (2012) Selective BRAF inhibitors induce marked T-cell infi ltration into human metastatic melanoma. Clin Cancer Res 18(5):1386-1394
-
(2012)
Clin Cancer Res
, vol.18
, Issue.5
, pp. 1386-1394
-
-
Wilmott, J.S.1
Long, G.V.2
Howle, J.R.3
-
46
-
-
80052485771
-
Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefi tinib
-
Oxnard GR, Janjigian YY, Arcila ME et al (2011) Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefi tinib. Clin Cancer Res 17(19): 6322-6328
-
(2011)
Clin Cancer Res
, vol.17
, Issue.19
, pp. 6322-6328
-
-
Oxnard, G.R.1
Janjigian, Y.Y.2
Arcila, M.E.3
-
47
-
-
65649133474
-
Final results of the sunbelt melanoma trial
-
suppl): Abstr 9003
-
McMasters KM, Ross MI, Reintgen DS et al (2008) Final results of the Sunbelt Melanoma Trial. J Clin Oncol 26(suppl): Abstr 9003
-
(2008)
J Clin Oncol
, vol.26
-
-
McMasters, K.M.1
Ross, M.I.2
Reintgen, D.S.3
-
48
-
-
84857038232
-
Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?
-
Eggermont AM, Spatz A, Lazar V, Robert C (2012) Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity? Curr Opin Oncol 24(2):137-140
-
(2012)
Curr Opin Oncol
, vol.24
, Issue.2
, pp. 137-140
-
-
Eggermont, A.M.1
Spatz, A.2
Lazar, V.3
Robert, C.4
-
49
-
-
84866945192
-
FC13 DERMA Phase III trial of MAGE-A3 immunotherapy as adjuvant treatment in stage III melanoma: MAGE-A3 gene expression frequency and baseline demographics
-
Trefzer U, Jouary T, Robert C et al (2010) FC13 DERMA Phase III trial of MAGE-A3 immunotherapy as adjuvant treatment in stage III melanoma: MAGE-A3 gene expression frequency and baseline demographics. Melanoma Res 20:e34-e35
-
(2010)
Melanoma Res
, vol.20
-
-
Trefzer, U.1
Jouary, T.2
Robert, C.3
-
50
-
-
0023888654
-
Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells
-
Atkins MB, Mier JW, Parkinson DR et al (1988) Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 318(24):1557-1563
-
(1988)
N Engl J Med
, vol.318
, Issue.24
, pp. 1557-1563
-
-
Atkins, M.B.1
Mier, J.W.2
Parkinson, D.R.3
-
51
-
-
32644454916
-
Prognostic significance of autoimmunity during treatment of melanoma with interferon
-
Gogas H, Ioannovich J, Dafni U et al (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354(7):709-718
-
(2006)
N Engl J Med
, vol.354
, Issue.7
, pp. 709-718
-
-
Gogas, H.1
Ioannovich, J.2
Dafni, U.3
-
52
-
-
58149396712
-
Prognostic significance of serum s100b protein in high-risk surgically resected melanoma patients participating in intergroup trial ecog 1694
-
Tarhini AA, Stuckert J, Lee S, Sander C, Kirkwood JM (2009) Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol 27(1):38-44
-
(2009)
J Clin Oncol
, vol.27
, Issue.1
, pp. 38-44
-
-
Tarhini, A.A.1
Stuckert, J.2
Lee, S.3
Sander, C.4
Kirkwood, J.M.5
-
53
-
-
79952008364
-
Autoimmunity and treatment outcome in melanoma
-
Bouwhuis MG, Ten Hagen TL, Suciu S, Eggermont AM (2011) Autoimmunity and treatment outcome in melanoma. Curr Opin Oncol 23(2):170-176
-
(2011)
Curr Opin Oncol
, vol.23
, Issue.2
, pp. 170-176
-
-
Bouwhuis, M.G.1
Ten Hagen, T.L.2
Suciu, S.3
Eggermont, A.M.4
-
55
-
-
58149396712
-
Prognostic significance of serum s100b protein in high-risk surgically resected melanoma patients participating in intergroup trial ecog 1694
-
Tarhini AA, Stuckert J, Lee S, Sander C, Kirkwood JM (2009) Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol 27(1):38-44
-
(2009)
J Clin Oncol
, vol.27
, Issue.1
, pp. 38-44
-
-
Tarhini, A.A.1
Stuckert, J.2
Lee, S.3
Sander, C.4
Kirkwood, J.M.5
-
56
-
-
37049002728
-
Interferon alfa-induced autoimmunity and serum S100 levels as predictive and prognostic biomarkers in high-risk melanoma in the ECOG-intergroup phase II trial E2696
-
ASCO Annual Meeting Proceedings Part I 25, no. 18S (June 20 Supplement
-
Stuckert JJ, Tarhini AA, Lee S et al (2007) Interferon alfa-induced autoimmunity and serum S100 levels as predictive and prognostic biomarkers in high-risk melanoma in the ECOG-intergroup phase II trial E2696. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I, vol 25, no. 18S (June 20 Supplement): 8506
-
(2007)
J Clin Oncol
, vol.2007
, pp. 8506
-
-
Stuckert, J.J.1
Tarhini, A.A.2
Lee, S.3
-
57
-
-
79251599240
-
Prognostic value of serial blood s100b determinations in stage iib-iii melanoma patients: A corollary study to eortc trial 18952
-
Bouwhuis MG, Suciu S, Kruit W et al (2011) Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: A corollary study to EORTC trial 18952. Eur J Cancer 47(3):361-368
-
(2011)
Eur J Cancer
, vol.47
, Issue.3
, pp. 361-368
-
-
Bouwhuis, M.G.1
Suciu, S.2
Kruit, W.3
-
58
-
-
67449138506
-
Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon
-
Bouwhuis MG, Suciu S, Collette S et al (2009) Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J Natl Cancer Inst 101(12):869-877
-
(2009)
J Natl Cancer Inst
, vol.101
, Issue.12
, pp. 869-877
-
-
Bouwhuis, M.G.1
Suciu, S.2
Collette, S.3
-
59
-
-
79960701540
-
Changes of ferritin and CRP levels in melanoma patients treated with adjuvant interferon-α EORTC 18952) and prognostic value on treatment outcome
-
Bouwhuis MG, Collette S, Suciu S et al (2011) Changes of ferritin and CRP levels in melanoma patients treated with adjuvant interferon-α (EORTC 18952) and prognostic value on treatment outcome. Melanoma Res 21(4):344-351
-
(2011)
Melanoma Res
, vol.21
, Issue.4
, pp. 344-351
-
-
Bouwhuis, M.G.1
Collette, S.2
Suciu, S.3
-
60
-
-
77952469658
-
Phase III trial comparing adjuvant treatment with pegylated interferon alfa-2b versus observation: Prognostic significance of autoantibodies -eortc 18991
-
Bouwhuis MG, Suciu S, Testori A et al (2010) Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: Prognostic significance of autoantibodies -EORTC 18991. J Clin Oncol 28(14): 2460-2466
-
(2010)
J Clin Oncol
, vol.28
, Issue.14
, pp. 2460-2466
-
-
Bouwhuis, M.G.1
Suciu, S.2
Testori, A.3
|